Author

Nithya Selvan

OpenAlex ID: A5044555735

Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease

2023 · Bishnu P. De, Jonathan B. Rosenberg, et al. · Human Gene Therapy · 12

Expression and processing of mature human frataxin after gene therapy in mice

2024 · Teerapat Rojsajjakul, Nithya Selvan, et al. · Scientific Reports · 8

Abstract 13599: LX2020, an Adeno Associated Viral-Based Plakophilin 2 Gene Therapy Stabilizes Cardiac Disease Phenotype in a Severe Mouse Model of Arrhythmogenic Right Ventricular Cardiomyopathy

2022 · Farah Sheikh, Jing Zhang, et al. · Circulation · 8

Preclinical efficacy and safety of AAVrh10-based plakophilin-2 gene therapy (LX2020) as a treatment for arrhythmogenic cardiomyopathy

2025 · Jing Zhang, Erika Joana Gutierrez-Lara, et al. · npj Regenerative Medicine · 6

Topline results from Phase 1/2 AAV gene therapy (LX1001) in APOE4/4 homozygotes with Alzheimer’s disease

2025 · Kim G Johnson, Michael Kaplitt, et al. · Alzheimer s & Dementia · 5

Validation of Anti-Adeno Associated Virus Serotype rh10 (AAVrh.10) Total and Neutralizing Antibody Immunogenicity Assays

2023 · Elizabeth Butala-Flores, Thien Nguyen, et al. · Pharmaceutical Research · 4

AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia

2026 · Ronald G. Crystal, Jonathan W. Weinsaft, et al. · JAMA Cardiology · 3

Abstract We117: Preclinical Evidence of Long-term Efficacy and Safety of LX2020, an AAV based Plakophilin-2 Gene Therapy, for the Treatment of Arrhythmogenic Cardiomyopathy

2024 · Jing Zhang, Erika Joana Gutierrez Lara, et al. · Circulation Research

Abstract 18583: Preclinical Efficacy and Safety of Intravenously Administered LX2020 Gene Therapy for the Treatment of Arrhythmogenic Cardiomyopathy

2023 · Farah Sheikh, Jing Zhang, et al. · Circulation

Works count: 9

Citation count: 46

H-index: 5

I10-index: 1